Evidence map›Paper›PMID 28868508›Full record

ArticleInvestigative and clinical urology2017

Can men with prostates sized 80 mL or larger be managed conservatively?

Alvin Lee, Han Jie Lee, Keong Tatt Foo

Open access · diamondAbstract read
In one paragraph

Article in Investigative and clinical urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Investigative and clinical urology · 2023
    Trial
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alvin LeeDepartment of Urology, Singapore General Hospital, Singapore.
Han Jie LeeDepartment of Urology, Singapore General Hospital, Singapore.
Keong Tatt FooDepartment of Urology, Singapore General Hospital, Singapore.
Singapore General Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo analyze the long-term clinical outcomes of men with large prostate sizes of 80 mL and greater who were managed conservatively. MATERIALS AND

methodsWe retrospectively analyzed men with prostate sizes of 80 mL and greater from our electronic hospital database. Clinical parameters such as age, International Prostate Symptom Score (IPSS), quality of life (QoL) scoring, serum prostate-specific antigen (PSA), uroflowmetry variables, and transabdominal ultrasound findings were evaluated. These parameters were compared at entry to our study and at the patient's latest follow-up visit.

resultsFor the 50 men included in our analysis, mean age was 68 years, median PSA was 9.9 ng/mL, and median prostate volume was 94 mL. Seven men underwent upfront prostate surgery, whereas the other 43 were managed conservatively, predominantly with pharmacotherapy (98%). Only serum PSA, QoL scores, and postvoid residual urine demonstrated a significant reduction at the end of a median follow-up period of 62 months. Fourteen men (33%) were considered to have progressed clinically, with 8 experiencing retention of urine and 6 having symptomatic deterioration. Of the 35 men who were still receiving conservative treatment at the end of the follow-up period, 24 men (69%) had a peak flow rate of 10 mL/s or greater, a QoL score of 3 or less, and mild to moderate (IPSS, 0-19) symptoms.

conclusionsAlthough the incidence of clinical progression in men with prostate sizes of 80 mL and greater is high, there is still a role for conservative management with pharmacotherapy.

Indexed as

Watchful Waiting5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsAgedAged, 80 and overDatabases, FactualDisease ProgressionFollow-Up StudiesHumansMaleMiddle AgedPrognosisProstateProstatectomyProstate-Specific AntigenProstatic Hyperplasia5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsProstate-Specific AntigenConservative treatmentNatural historyProstatic hyperplasia

Identifiers

PMID28868508
PMCPMC5577333
OpenAlexW2750948382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.